Topical CBD gel reduced joint swelling, inflammation, and pain behaviors in arthritic rats at doses of 6.2 mg/day and above — without CNS side effects — providing the first rigorous evidence for CBD topical products.
Anyone using or considering CBD cream for joint pain; arthritis patients; consumers evaluating CBD topical products.
>50% reduction in synovial membrane thickening at effective CBD doses
The Backstory
Walk into any pharmacy, health food store, or gas station in America and you'll find CBD cream marketed for joint pain. The labels promise relief from arthritis, inflammation, sore muscles. The price tags suggest confidence. But in 2016, when D.C. Hammell's team at the University of Kentucky published this study, almost none of these products had any scientific evidence behind them.
Hammell's study didn't test a commercial product. It tested a fundamental question: can CBD, applied to the skin, actually reach joint tissue, reduce inflammation, and relieve pain? The answer — in rats, with caveats — was yes. And it provided the first rigorous evidence for something millions of consumers were already buying.
The Experiment
The team used a standard arthritis model: injecting Complete Freund's adjuvant into one knee joint of Sprague-Dawley rats to create inflammation, swelling, and pain that mimics human inflammatory arthritis. Then they applied CBD gel at four different doses (0.6, 3.1, 6.2, and 62.3 mg/day) directly to the skin over the affected joint for four consecutive days.
How They Did It
How They Tested Topical CBD
Induce Arthritis
Complete Freund's adjuvant injected into one knee joint, creating inflammatory arthritis with measurable swelling, pain behaviors, and inflammatory biomarkers.
A well-established preclinical model that produces predictable, quantifiable inflammation
Apply CBD Gel
Transdermal CBD gel applied directly to the skin over the arthritic joint at four dose levels for four days.
Doses: 0.6, 3.1, 6.2, and 62.3 mg/day — allowing dose-response analysis
Measure Inflammation
Joint circumference (swelling), synovial membrane thickness, and immune cell infiltration assessed.
Both gross anatomy and histological analysis
Measure Pain
Paw withdrawal latency (how quickly the animal pulls away from a stimulus) and limb posture scores (spontaneous pain).
Standard behavioral assays for pain in rodent models
Measure Neural Markers
Spinal cord CGRP and OX42 (inflammation markers), dorsal root ganglia TNFα, and exploratory behavior.
Distinguishing local anti-inflammatory effects from central nervous system effects
Hammell et al. (2016), Eur J Pain 20(6):936-948
The Results
CBD for Arthritis
What Topical CBD Did in Arthritic Rats
>50%
Reduced synovial thickening
at higher doses
Dose-dependent
Joint swelling reduction
significant at 6.2 and 62.3 mg/day
Restored
Pain thresholds
paw withdrawal latency recovered toward baseline
Zero
CNS side effects
exploratory behavior unchanged
Hammell et al. (2016), Eur J Pain
The dose-response was clean. At the lowest dose (0.6 mg/day), effects were minimal. At 6.2 and 62.3 mg/day, CBD significantly reduced joint swelling, decreased synovial membrane thickening by over 50%, diminished immune cell infiltration, and restored pain behaviors toward baseline. The highest dose didn't work dramatically better than the middle dose — suggesting a ceiling effect rather than a linear relationship.
The neural markers told an important story: CBD reduced CGRP and OX42 in the spinal cord and TNFα in the dorsal root ganglia, all in a dose-dependent manner. This means CBD wasn't just reducing inflammation locally — it was dampening the pain signaling cascade from the joint through the nervous system.
Critically, exploratory behavior was unaffected. The rats didn't become sedated, disoriented, or less active. This confirmed that topical CBD was working locally and through peripheral nerve pathways, not by crossing into the brain and producing systemic effects.
Why an Animal Study Matters Here
Preclinical Evidence
Why This Rat Study Is Important
It proved penetration
CBD applied to the skin actually reaches the joint tissue underneath. This wasn't obvious — many topical compounds sit on the skin surface without therapeutic concentrations reaching deeper structures.
It showed dose-response
Higher doses worked better, following a predictable pharmacological curve. Random effects don't follow dose-response patterns — drug effects do.
It demonstrated selectivity
CBD reduced inflammation and pain without affecting normal brain function (no CNS side effects). This selectivity is rare and therapeutically valuable.
It grounded a consumer market
By 2016, CBD topicals were already a multi-billion-dollar market running on testimonials. This study provided the first rigorous evidence that the mechanism was pharmacologically plausible.
The caveat is real
Rats are not humans. Their skin is thinner, their joints are smaller, and the arthritis model is artificially induced. Human inflammatory arthritis is more complex and more variable.
Hammell et al. (2016)
The rat-to-human gap matters. Dozens of promising preclinical findings have failed to translate to clinical benefit. But this study did something most CBD research hadn't: it showed a complete mechanistic chain from application to tissue penetration to inflammatory marker reduction to behavioral pain improvement — all with dose-response confirmation.
What This Means for CBD Topical Products
Myth vs. Reality
CBD cream works because CBD is a powerful anti-inflammatory that penetrates skin and heals joints.
This study showed that CBD gel CAN penetrate skin and reduce inflammation in rat joints at specific doses. But most commercial CBD topicals contain far less CBD than the effective doses in this study, use different formulations that may not penetrate skin as well, and have never been tested in human arthritis trials. The preclinical mechanism is real. Whether your specific product delivers a therapeutic dose to your specific joint is unknown.
The Evidence
Effective doses were 6.2-62.3 mg/day applied directly to the joint in a gel formulation optimized for skin penetration. Many commercial products contain 100-500mg CBD per container, applied over large areas — resulting in much lower per-joint concentrations. No human RCT of topical CBD for arthritis has been published as of 2026.
Hammell et al. (2016); consumer product analysis
For the millions of people with arthritis who use or consider CBD, this study provides genuine encouragement — and necessary caution. The biology is plausible. The preclinical evidence is solid. But the translation to human clinical use remains unproven, and the quality and dosing of commercial products varies enormously.
Related Research
CBD, Pain, and Inflammation
From preclinical promise to clinical questions — the evidence chain for CBD and pain.
Cannabinoids for Medical Use
Whiting et al. (2015)
The comprehensive evidence review — showing moderate evidence for cannabinoids and chronic pain, though primarily studying oral/inhaled rather than topical routes
Cannabis for chronic pain: BMJ systematic review
Wang et al. (2021)
The most rigorous meta-analysis — only 2 of 32 trials used topical preparations, highlighting how understudied the route Hammell tested actually is
CBD for arthritis in dogs
Gamble et al. (2018)
Oral CBD reduced arthritis pain in dogs (no placebo bias possible) — complementary evidence from a different species and route of administration
Cannabis opioid substitution
Boehnke et al. (2016)
64% of medical cannabis patients reduced opioid use — topical CBD could be part of this substitution pattern for joint pain
Does CBD cream really work for arthritis?
In rats with induced arthritis, topical CBD gel significantly reduced joint swelling, inflammation, and pain behaviors at doses of 6.2 mg/day and above — without CNS side effects. However, no human randomized controlled trial of topical CBD for arthritis has been published. The preclinical evidence is solid, but human evidence is lacking. If you use CBD topicals for arthritis, look for products with third-party lab testing and higher CBD concentrations, and apply generously to the affected joint.
How much CBD needs to be in the cream for it to work?
In this study, effective doses were 6.2 to 62.3 mg/day applied directly to the affected joint in a formulation designed for skin penetration. Translating rat doses to human doses is imprecise, but the implication is that meaningful amounts of CBD need to reach the joint tissue — which requires both adequate concentration in the product and a formulation that actually penetrates skin. Many commercial products may not meet this bar.
Can CBD replace arthritis medication?
This study cannot answer that question — it tested CBD in rats, not humans, and compared to vehicle (carrier), not to existing arthritis drugs. For people with arthritis, CBD topicals should be considered a potential complement to, not replacement for, evidence-based treatments. Discuss any changes with your rheumatologist.
What the researchers found
Transdermal CBD at 6.2 and 62.3 mg/day significantly reduced joint circumference, synovial membrane thickening (>50%), immune cell infiltration, pain behaviors, and neural inflammation markers (CGRP, OX42, TNFα) in a dose-dependent manner without CNS side effects.
Why it matters
First rigorous preclinical evidence that topical CBD can penetrate skin, reach joint tissue, and produce anti-inflammatory and analgesic effects — grounding a multi-billion-dollar consumer market that previously ran on testimonials.
How the study worked
Complete Freund adjuvant-induced monoarthritis in Sprague-Dawley rats. CBD gel applied topically at 4 dose levels (0.6, 3.1, 6.2, 62.3 mg/day) for 4 days. Outcomes: joint circumference, histology, pain behaviors (paw withdrawal latency, limb posture), spinal/DRG inflammatory markers, exploratory behavior.
What this study cannot tell us
Animal model only — rat skin is thinner than human skin. Arthritis was artificially induced. Short duration (4 days). No comparison to existing arthritis treatments. Commercial CBD products differ substantially from research formulations. No human data.
How to read the evidence
Strong preclinical evidence with clean dose-response. But animal studies are the lowest tier of clinical evidence — no human RCT exists for topical CBD arthritis treatment.
When this study was published
Published 2016 — still the primary preclinical reference for CBD topicals. No human RCT has followed as of 2026.
The bigger picture
CBD topicals are one of the largest cannabis product categories globally. This study provided the first pharmacological justification — but human RCTs are still missing. The gap between preclinical promise and clinical proof remains the central challenge.
Questions still open
- Do these results translate to human arthritis? What formulation factors determine skin penetration? How do commercial products compare to research-grade CBD gel?
Common questions
Read the original research
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.
European Journal of Pain, 20(6), 936-948
Citation
Hammell, D C; Zhang, L P; Ma, F; Abshire, S M; McIlwrath, S L; Stinchcomb, A L; Westlund, K N. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.. European Journal of Pain, 20(6), 936-948. https://doi.org/10.1002/ejp.818